Drug Trial Radar · NCT07192588
A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
273
Planned (sponsor's estimate)
Start
Jul 26, 2024
Primary completion
Sep 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Graegis Pharmaceuticals LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Excelya
- First posted
- Sep 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is testing a new skin gel called GR1014-CG to evaluate its safety and see if it can help prevent or reduce skin irritation (such as redness, soreness, etc.) caused by radiation therapy (RT) after breast-conserving surgery for early-stage breast cancer. The study is for women aged 18 and older who have had surgery to remove a breast tumor and need radiation therapy. The main goals of the study are to find out: * If GR1014-CG is safe to use * If the gel can prevent or lower the severity of skin irritation caused by RT. During the study participants will, * Be randomly assigned to use one of two strengths of GR1014-CG (4.7% or 2.4%) or a placebo gel (a gel with no active drug). * Apply the gel to the breast before each radiation session for 5 days. * Visit the clinic once a week for 4 weeks to check their skin and overall health. At the end of the 4th week, if there are still signs of irritation participants will come to the clinic for a checkup 2 weeks after, and then again 2 weeks after if the irritation is still observed. * Keep a diary to record any pain or itching they may feel.
Conditions
- Radiodermatitis; Acute
Interventions
GR1014-CG 2.4%Drug
Topical gel formulation of amifostine thiol (GR1014) at 25 mg/mL
Vehicle GelDrug
The same topical formulation as GR1014-CG without the active ingredient amifostine thiol
Radiation TherapyRadiation
Ultra hypofractionated RT, 26 Gy in 5 daily fractions (5.2 Gy) given over 1 week on the whole breast
GR1014-CG 4.7%Drug
Topical gel formulation of amifostine thiol (GR1014) at 50 mg/mL
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with No Radiation Dermatitis as Assessed by CTCAE Latest Version (LV) (Grade of 0)Time frame: At any time between the first radiotherapy session and 4 weeks after the last one
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Institut Bergonié
Bordeaux, France
Centre Léon Bérard
Lyon, France
Institut Gustave Roussy
Villejuif, France
The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.